|
1）Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011; 17: 175-8
|
|
|
|
2）Orru CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014; 371: 519-29
|
|
|
|
|
|
3）Moda F, Gambetti P, Notari S, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med. 2014; 371: 530-9
|
|
|
|
|
|
4）Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009; 8: 334-44
|
|
|
|
|
|
5）Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013; 81: 2015-23
|
|
|
|
|
|
6）Haik S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 13: 150-8
|
|
|
|
|
|
7）Brown P, Cathala F, Raubertas RF, et al. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology. 1987; 37: 895-904
|
|
|
|
|
|
8）Nozaki I, Hamaguchi T, Sanjo N, et al. Prospective 10-year surveillance of human prion diseases in Japan. Brain. 2010; 133: 3043-57
|
|
|
|
|
|
9）Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999; 46: 224-33
|
|
|
|
|
|
10）Doh-ura K, Kitamoto T, Sakaki Y, et al. CJD discrepancy. Nature. 1991; 353: 801-2
|
|
|
|
|
|
11）Global surveillance, diagnosis, and therapy of human transmissible spongiform encephalopathies. Report of a WHO consultation; 9-11 February 1998; Geneva (http://www.int/csr/resources/publications:bse/WHO_EMC_ZDI_98_9/en/)
|
|
|
|
|
|
12）Hamaguchi T, Kitamoto T, Sato T, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology. 2005; 64: 643-8
|
|
|
|
|
|
13）Castellani RJ, Colucci M, Xie Z, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology. 2004; 63: 436-42
|
|
|
|
|
|
14）Gmitterova K, Heinemann U, Bodemer M, et al. 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging. 2009; 30: 1842-50
|
|
|
|
|
|
15）Meissner B, Westner IM, Kallenberg K, et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology. 2005; 65: 1544-50
|
|
|
|
|
|
16）Jin K, Shiga Y, Shibuya S, et al. Clinical features of Creutzfeldt-Jakob disease with V180I mutation. Neurology. 2004; 62: 502-5
|
|
|
|
|
|
17）Shiga Y, Satoh K, Kitamoto T, et al. Two different clinical phenotypes of Creutzfeldt-Jakob disease with a M232R substitution. J Neurol. 2007; 254: 1509-17
|
|
|
|
|
|
18）Yamada M, Tomimitsu H, Yokota T, et al. Involvement of the spinal posterior horn in Gerstmann-Sträussler-Scheinker disease (PrP P102L). Neurology. 1999; 52: 260-5
|
|
|
|
|
|
19）Ladogana A, Sanchez-Juan P, Mitrova E, et al. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol. 2009; 256: 1620-8
|
|
|
|
|
|
20）Montagna P, Gambetti P, Cortelli P, et al. Familial and sporadic fatal insomnia. Lancet Neurol. 2003; 2: 167-76
|
|
|
|
|
|
21）Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992; 326: 444-9
|
|
|
|
|
|
22）Brown P, Brandel JP, Sato T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis. 2012; 18: 901-7
|
|
|
|
|
|
23）Noguchi-Shinohara M, Hamaguchi T, Kitamoto T, et al. Clinical features and diagnosis of dura mater graft associated Creutzfeldt Jakob disease. Neurology. 2007; 69: 360-7
|
|
|
|
|
|
24）Yamada M. The first Japanese case of variant Creutzfeldt-Jakob disease showing periodic electroencephalogram. Lancet. 2006; 367: 874
|
|
|
|
|
|
25）Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol. 2000; 47: 575-82
|
|
|
|
|
|
26）World Organisation for animal health. Number of cases of bovine spongiform encephalopathy (BSE) reported in the United Kingdom (http://wwwoieint/animal-health-in-the-world/bse-specific-data/number-of-cases-in-the-united-kingdom/)
|
|
|
|
|
|
27）Hosokawa-Muto J, Kamatari YO, Nakamura HK, et al. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity. Antimicrob Agents Chemother. 2009; 53: 765-71
|
|
|
|
|
|
28）Kamatari YO, Hayano Y, Yamaguchi K, et al. Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones. Protein Sci. 2013; 22: 22-34
|
|
|
|
|
|
29）水澤英洋，塚本 忠，三條伸夫，他．遺伝性プリオン病患者登録・評価・介入ユニット（trial unit）の構築. 厚生労働科学研究委託事業難治性疾患克服研究事業「プリオン病及び遅発性ウイルス感染症の分子病態解明・治療法開発に関する研究」平成26年度委託業務成果報告書．2015. p.53-5
|
|
|
|
|